A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
NCT ID: NCT00111631
Last Updated: 2016-11-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
218 participants
INTERVENTIONAL
2005-05-31
2006-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
DPP-IV Inhibitor
Escalating doses po bid
Metformin
As prescribed
2
DPP-IV Inhibitor
Escalating doses po bid
Metformin
As prescribed
3
DPP-IV Inhibitor
Escalating doses po bid
Metformin
As prescribed
4
Metformin
As prescribed
Placebo
po bid
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DPP-IV Inhibitor
Escalating doses po bid
Metformin
As prescribed
Placebo
po bid
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* type 2 diabetes;
* stable metformin therapy for \>=3 months before screening.
Exclusion Criteria
* type 1 diabetes;
* any anti-hyperglycemic medication other than metformin in the last 3 months.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Concord, California, United States
Salinas, California, United States
San Diego, California, United States
Boulder, Colorado, United States
Newark, Delaware, United States
Wilmington, Delaware, United States
Clearwater, Florida, United States
Miami, Florida, United States
Chicago, Illinois, United States
Detroit, Michigan, United States
Buffalo, New York, United States
Rochester, New York, United States
Durham, North Carolina, United States
Mogadore, Ohio, United States
Portland, Oregon, United States
Connellsville, Pennsylvania, United States
Warminster, Pennsylvania, United States
Dallas, Texas, United States
Midland, Texas, United States
San Antonio, Texas, United States
Adelaide, , Australia
Sydney, , Australia
Winnipeg, Manitoba, Canada
Halifax, Nova Scotia, Canada
London, Ontario, Canada
Toronto, Ontario, Canada
Bad Lauterberg im Harz, , Germany
Berlin, , Germany
Dresden, , Germany
Görlitz, , Germany
Mainz, , Germany
Neuss, , Germany
Ancona, , Italy
Florence, , Italy
Napoli, , Italy
Udine, , Italy
Ponce, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BM18106
Identifier Type: -
Identifier Source: org_study_id